Cargando…

Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country

BACKGROUND: The World Health Organization recommends establishing and implementing a national pharmaceutical policy (NPP) to guarantee effective and equitable access to medicines. Mexico has implemented several policy approaches to regulate the pharmaceutical sector, but it has no formal NPP. This a...

Descripción completa

Detalles Bibliográficos
Autores principales: Moye-Holz, Daniela, van Dijk, Jitse P, Reijneveld, Sijmen A., Hogerzeil, Hans V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540413/
https://www.ncbi.nlm.nih.gov/pubmed/28764738
http://dx.doi.org/10.1186/s12992-017-0281-1
_version_ 1783254628419239936
author Moye-Holz, Daniela
van Dijk, Jitse P
Reijneveld, Sijmen A.
Hogerzeil, Hans V.
author_facet Moye-Holz, Daniela
van Dijk, Jitse P
Reijneveld, Sijmen A.
Hogerzeil, Hans V.
author_sort Moye-Holz, Daniela
collection PubMed
description BACKGROUND: The World Health Organization recommends establishing and implementing a national pharmaceutical policy (NPP) to guarantee effective and equitable access to medicines. Mexico has implemented several policy approaches to regulate the pharmaceutical sector, but it has no formal NPP. This article describes the approach that the Mexican government has taken to improve availability and affordability of essential medicines. METHODS: Descriptive policy analysis of public pharmaceutical policy proposals and health action plans on the basis of publicly available data and health progress reports, with a focus on availability and affordability of medicines. RESULTS: The government has implemented pooled procurement, price negotiations, and an information platform in the public sector to improve affordability and availability. The government mainly reports on the savings that these strategies have generated in the public expenditure but their full impact on availability and affordability has not been assessed. CONCLUSIONS: To increase availability and affordability of medicines in the public sector, the Mexican government has resorted on isolated strategies. In addition to efficient procurement, price negotiations and price information, other policy components and pricing interventions are needed. All these strategies should be included in a comprehensive NPP.
format Online
Article
Text
id pubmed-5540413
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55404132017-08-03 Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country Moye-Holz, Daniela van Dijk, Jitse P Reijneveld, Sijmen A. Hogerzeil, Hans V. Global Health Research BACKGROUND: The World Health Organization recommends establishing and implementing a national pharmaceutical policy (NPP) to guarantee effective and equitable access to medicines. Mexico has implemented several policy approaches to regulate the pharmaceutical sector, but it has no formal NPP. This article describes the approach that the Mexican government has taken to improve availability and affordability of essential medicines. METHODS: Descriptive policy analysis of public pharmaceutical policy proposals and health action plans on the basis of publicly available data and health progress reports, with a focus on availability and affordability of medicines. RESULTS: The government has implemented pooled procurement, price negotiations, and an information platform in the public sector to improve affordability and availability. The government mainly reports on the savings that these strategies have generated in the public expenditure but their full impact on availability and affordability has not been assessed. CONCLUSIONS: To increase availability and affordability of medicines in the public sector, the Mexican government has resorted on isolated strategies. In addition to efficient procurement, price negotiations and price information, other policy components and pricing interventions are needed. All these strategies should be included in a comprehensive NPP. BioMed Central 2017-08-01 /pmc/articles/PMC5540413/ /pubmed/28764738 http://dx.doi.org/10.1186/s12992-017-0281-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Moye-Holz, Daniela
van Dijk, Jitse P
Reijneveld, Sijmen A.
Hogerzeil, Hans V.
Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country
title Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country
title_full Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country
title_fullStr Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country
title_full_unstemmed Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country
title_short Policy approaches to improve availability and affordability of medicines in Mexico – an example of a middle income country
title_sort policy approaches to improve availability and affordability of medicines in mexico – an example of a middle income country
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540413/
https://www.ncbi.nlm.nih.gov/pubmed/28764738
http://dx.doi.org/10.1186/s12992-017-0281-1
work_keys_str_mv AT moyeholzdaniela policyapproachestoimproveavailabilityandaffordabilityofmedicinesinmexicoanexampleofamiddleincomecountry
AT vandijkjitsep policyapproachestoimproveavailabilityandaffordabilityofmedicinesinmexicoanexampleofamiddleincomecountry
AT reijneveldsijmena policyapproachestoimproveavailabilityandaffordabilityofmedicinesinmexicoanexampleofamiddleincomecountry
AT hogerzeilhansv policyapproachestoimproveavailabilityandaffordabilityofmedicinesinmexicoanexampleofamiddleincomecountry